Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	61679
Country	China

Received	2020-12-21 02:19
Peer-Review Started	2020-12-16 01:31
To Make the First Decision
Return for Revision	2021-01-11 05:06
Revised	2021-01-18 16:37
Second Decision	2021-01-27 03:32
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-02-04 22:05
Articles in Press	2021-02-04 22:05
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-02-26 11:08
Typeset the Manuscript	2021-03-05 12:50
Publish the Manuscript Online	2021-03-09 08:51

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Angiotensin-converting enzyme 2 connects COVID-19 with cancer and cancer immunotherapy
Manuscript Source	Invited Manuscript
All Author List	Xiao-Sheng Wang
ORCID	Author(s) ORCID Number Xiao-Sheng Wang http://orcid.org/0000-0002-7199-7093
Funding Agency and Grant Number
Corresponding Author	Xiao-Sheng Wang, PhD, Associate Professor, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, No. 639 Longmian Avenue, Nanjing 211198, Jiangsu Province, China. xiaosheng.wang@cpu.edu.cn
Key Words	Angiotensin-converting enzyme 2; COVID-19; Cancer progression; Antitumor immune responses; Cancer immunotherapy
Core Tip	Angiotensin-converting enzyme 2 (ACE2) is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host cell receptor and plays a crucial role in SARS-CoV-2 invading human cells to cause coronavirus disease 2019 (COVID-19). ACE2 also plays a role in preventing tumor progression and promoting cancer immunotherapy response. Thus, the use of ACE2 inhibitors to prevent and treat COVID-19 should be cautious for cancer patients.
Publish Date	2021-03-09 08:51
Citation	Wang XS. Angiotensin-converting enzyme 2 connects COVID-19 with cancer and cancer immunotherapy. World J Gastrointest Oncol 2021; 13(3): 157-160
URL	https://www.wjgnet.com/1948-5204/full/v13/i3/157.htm
DOI	https://dx.doi.org/10.4251/wjgo.v13.i3.157

Full Article (PDF)	WJGO-13-157.pdf
Full Article (Word)	WJGO-13-157.docx
Manuscript File	61679_Auto_Edited_LM-Webster J_Wang-Clear.docx
Answering Reviewers	61679-Answering reviewers.pdf
Audio Core Tip	61679-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	61679-Conflict-of-interest statement.pdf
Copyright License Agreement	61679-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	61679-Language certificate.pdf
Peer-review Report	61679-Peer-review(s).pdf
Scientific Misconduct Check	61679-Bing-Ma YJ-1.jpg
Scientific Misconduct Check	61679-Bing-Fan JR-2.png
Scientific Misconduct Check	61679-Scientific misconduct check.pdf
Scientific Editor Work List	61679-Scientific editor work list.pdf